CombiMatrix Molecular Diagnostics last week launched its melanoma test, a diagnostic that it claims can discriminate malignant melanoma from benign moles.
The expression-based test, which runs on CombiMatrix’s CustomArray platform, could enable pathologists to resolve difficult-to-diagnose cases through an objective genetic analysis, CMDX parent CombiMatrix said.